Navigation Links
Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
Date:2/21/2012

AMSTERDAM, The Netherlands, February 21, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has received a request to provide additional information to the Committee for Human Medicinal Products (CHMP) on Glybera® (alipogene tiparvovec) by March 8, 2012. The CHMP request follows the announcement on January 30, 2012 that the European Commission Standing Committee was requesting additional information from the CHMP. The CHMP has indicated that a final decision on Glybera could be made by May 2012.

Glybera is a gene therapy for patients with the genetic disorder LPLD, a very rare inherited condition that is associated with increased levels of chylomicrons. These particles carry certain types of fat in the blood, which because they are not removed from the body can cause recurrent bouts of pancreatitis. There is no treatment currently available for these patients.

On October 23, 2011, AMT received a non-approvable opinion from the CHMP (following a re-examination of the marketing approval dossier originally rejected in June 2011) despite a recommendation to approve Glybera by the Committee for Advanced Therapies (CAT). The CAT is an expert body implemented by the European Commission to prepare and advise the CHMP on decisions regarding advanced therapeutics, in particular gene and cell therapies. 

AMT's proposed acquisition of assets by uniQure BV announced on February 17, 2012, was developed on the basis that Glybera is not approvable. This transaction will proceed as planned. In the event that Glybera could be commercialized in Europe, uniQure will evaluate how achieving this important milestone could be realized most efficiently.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency.

LPLD is an orphan disease for which no treatment ex
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
2. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
3. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
4. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
5. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
6. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
7. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
8. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
11. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Contego Medical, the first ... filter platform for angioplasty balloon and stent delivery ... Series B financing round led by Hatteras Venture ... focus on medical devices, biopharmaceuticals, diagnostics and related ... Mountain Group Partners, Lookout Capital and Medical Mutual. ...
(Date:4/17/2015)... NORTH CHICAGO, Ill. , April 17, 2015  AbbVie ... ABBV) today announced that it has extended the expiration of ... of common stock of Pharmacyclics, Inc. to 5 p.m., ... 2015. On April 17, 2015, AbbVie also ... Hart-Scott-Rodino Antitrust Improvements Act in order to provide the FTC ...
(Date:4/17/2015)... Inivata, a Cambridge, England -based ... the 2015 American Association for Cancer Research (AACR) Annual Meeting ... and a poster presentation. Michael Stocum , CEO ... nd . The presentation, entitled Monitoring the ... part of a session on Recent Advances in Diagnostics ...
Breaking Medicine Technology:Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... April 17, 2015 In Defense of ... following statement: “On Wednesday April 15th, the European Parliament ... a resolution recognizing the Armenian Genocide, “paying tribute, on ... the one-and-a-half million innocent Armenian victims who perished in ... extols the EU for this timely and needed recognition ...
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. Steven ... platelet-rich plasma (PRP) and stem cell therapy. ... for its world-class care of injury-caused and chronic joint ... in many other physicians offering regenerative medicines. , ... pain management and rehabilitation. Dr. Meier and MOSM can ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2
... that computerized prescription could be used to avoid medical mistakes, ... to even more errors. ,It is known that adverse ... hospitals each year. One way hospitals are trying to cut ... But according to a new study, use of computerized systems ...
... antihypertensive strategies that use calcium channel blockers and ... with beta-blockers and diuretics. ,Hypertensive patients either ... without the ACE inhibitor perindopril or the beta-blocker ... ,The trial ran for five years, but it ...
... common form of brain cancer might fare better with a ... ,Based on findings of the study it was seen ... glioblastoma receive surgery to remove as much of the cancer ... study compared 573 patients with glioblastomas who were randomized to ...
... say they have now identified a gene variant that ... which in turn could lead to improved understanding of ... to latest research it was seen that specific changes ... associated with an increased incidence of Alzheimer’s. ,In ...
... people it was found that men who drank six cups ... 12 to 18 years, while women who drank that amount ... their study revealed an unequivocal evidence for an inverse and ... other risk factors. However researchers say the reasons for ...
... Switzerland it was seen that the frequency of withholding ... a patient’s life varies greatly among European countries. The ... in diagnostics and treatment to save and sustain life. ... patient’s life, physicians may refrain from using all possible ...
Cached Medicine News:
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
Triad Plus PVP-I Prep Solution has broad-spectrum germicidal action. Povidone Iodine Solution using an innovative one-piece screw cap, Triad Plus bottles are designed specifically to meet the needs o...
... are packaged in easy open, single use, ... saturated with precisely the correct amount of ... saturated with a multi-purpose topical gel, for ... approved for venipuncture site preparation prior to ...
... Swabsticks are packaged in single-use ... Swabstick is saturated with precisely ... Each package is terminally sterilized, ... for the patient. Swabstick provides ...
Medicine Products: